Skip to main content
Premium Trial:

Request an Annual Quote

Vela Genomics NGS Clinical Interpretation and Reporting

Vela Genomics, a subsidiary of Vela Diagnostics, has launched TheraKey, a cloud-based, HIPAA-compliant, next-generation sequencing clinical interpretation and reporting solution. The TheraKey database includes somatic cancer mutations in more than 800 genes, sourced from approximately 220,000 clinical trials for about 2,000 cancer drugs. It also offers natural language processing to facilitate reporting of actionable treatments, including off-label, investigational, and combination therapies for specific diseases or gene variants. The firm will also offer TheraKey as part of its Sentosa NGS workflow for Oncology.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.